News + Press

Mastering the Market Intelligence Challenge

Posted December 5, 2017| Kimberlee Luce

To thrive in rapidly changing economies in regions such as Asia and Africa, multinationals need to take new approaches to gather and using market intelligence.

Multinational corporations have invested huge sums in emerging markets —more than $3 trillion since 1998, by one estimate. Returns from these investments, however, have sometimes been disappointing. The Economist, for example, has reported that the return on emerging-market investments for the average multinational corporation has been “mediocre” and that some companies “have lost a ton of money.”

Even when managers think they are performing well in emerging markets, they often are not because they have set low expectations. Executives at multinationals, for example, may be pleased with double-digit growth in revenues or being at their target profitability in emerging markets, yet their emerging-market operations may contribute only a tiny fraction of their overall business. With emerging-market companies rapidly gaining competitiveness, time for Western multinational companies to build market share in these countries is running out.

A frequently mentioned reason for the underperformance of multinational corporations in emerging markets is that these markets are different and that multinationals need to adapt their products and operations.

Read the rest of this MIT Sloan Management Review Article here.

Tags: , , , , , , , ,

Related Resources

Read More

Fuld + Company Welcomes Health & Life Sciences Practice Leader, Michael Ratcliffe

Michael Ratcliffe brings both deep industry expertise and intelligence and strategy consulting capabilities to the firm. Boston, Mass. November 26, […]

Read More

Fuld + Company Announces New, Senior Hire for Energy Practice

Keith McWhorter, MBA, Brings Strong Domain Knowledge, Strategy, Analysis and Research Capabilities to the Firm Boston, Mass. July 11, 2019—Fuld […]

Read More

Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End

To expand on the Fuld + Company, Pharma Companies to Watch Report, Analyst Robert Browne drilled in on the Biosimilar Marketplace in […]

Subscribe to our mailing list for our latest updates: